From Lukas
A boxed warning deserves attention, but it is not a prediction about every patient. We also examine a frailty trial, a rabies milestone that needs maintenance, and a biomarker result that missed its clinical endpoint.
Lukas DvorskyFounder of LongevityMate
The Big Signal
Why Injectafer now carries a boxed warning
Bottom line
A boxed warning makes a serious risk more visible; it is not a prediction about every patient.
Safety action
Boxed warning added
Symptomatic hypophosphatemia, Injectafer
Phosphate testing
<20% of episodes
FDA Sentinel examination
The communication gives no event rate and does not show equal risk for every patient or intravenous iron product.
What happened
On 1 September, the US Food and Drug Administration added a boxed warning for symptomatic hypophosphatemia, meaning low blood phosphate, to ferric carboxymaltose injection, sold as Injectafer. The action used post-marketing reports, literature and FDA Sentinel data. FDA found phosphate testing in fewer than 20% of the administration episodes it examined. The revised label advises testing people at risk and before a repeat course within three months.
Why it matters
Low phosphate can cause weakness, pain, fatigue, confusion, seizures or heart-rhythm problems. Reported serious consequences included hospital care, prolonged phosphate replacement, bone softening (osteomalacia) and fractures. The warning makes the risk more visible and highlights targeted monitoring and early action.
What this does not prove: The communication gives no event rate and does not show equal risk for every patient or intravenous iron product. Do not stop or change prescribed treatment without medical advice. Injectafer is a commercial medicine; the FDA communication has no investigator funding declaration.
Evidence: Safety / Regulatory · FDA safety action using post-marketing reports, literature and Sentinel data · 1 September 2026
Quick Signals
Signal 1
A year-long frailty programme improved measured function
What happened
A randomised trial enrolled 333 frail cardiovascular inpatients aged at least 70 at three hospitals in one Chinese city. A 12-month programme combined exercise, education, nutrition guidance, acupoint massage and medicine review; 252 people completed the primary assessment. Versus usual care, the adjusted differences were -0.79 on the Fried Frailty Phenotype and +2.02 on the Short Physical Performance Battery.
Why it matters
The coordinated programme improved frailty and physical-performance scores, while mortality was not significantly different. Participants and care teams were not blinded, and attrition and unequal contact matter. Public grants funded the study; funders reportedly had no role and authors declared no competing interests.
What this does not prove: The trial cannot identify which component caused the change, show longer life or independence, or prove the result transfers to every setting.
Evidence: Early · Randomised 12-month trial; 333 enrolled and 252 completed the primary assessment · 31 August 2026
Signal 2
Bhutan reached a rabies milestone that still needs maintenance
What happened
On 4 September, the World Health Organization validated Bhutan as the first country in its South-East Asia Region to eliminate dog-transmitted human rabies as a public-health problem. Bhutan reported no such deaths since June 2023. WHO reviewed a national dossier and conducted an August field mission.
Why it matters
Rabies is almost always fatal after symptoms begin, yet dog-transmitted human deaths can be prevented. Maintaining the milestone depends on dog vaccination, prompt post-exposure treatment and human-animal surveillance. Bhutan's Health Trust Fund and the Pandemic Fund were among the named supporters.
What this does not prove: Elimination as a public-health problem is not eradication. It does not mean zero animal rabies, permanent zero risk or that one programme component caused the result.
Evidence: Safety / Regulatory · Official WHO country validation based on dossier review and a field mission · 4 September 2026
Learn Corner
A boxed warning is a risk signal, not a forecast
A boxed warning is the FDA's most prominent way to flag a serious risk. It does not mean harm will happen to every person or give an individual probability when the evidence cannot support one. Check the exact risk, who may be vulnerable, the supporting evidence and the label's risk-reduction steps.
Read the editorial policyWhat We’re Watching
Pelacarsen lowered the blood marker Lp(a), but the outcome trial missed
sponsor-reported randomised phase 3 topline, incomplete
Novartis says Lp(a)HORIZON enrolled 8,323 people with cardiovascular disease and lowered the blood marker Lp(a), but missed its primary composite cardiovascular endpoint overall. Full data are pending. Event counts, effect size, confidence interval, achieved reduction and complete safety results are missing. Pelacarsen is not approved, and this announcement neither disproves the Lp(a) target nor establishes subgroup benefit. Novartis develops the medicine under an Ionis licence and issued the result.
Commercial interest: Novartis develops pelacarsen under an Ionis licence and issued the topline result.
We will return when complete published results, including event counts and safety, are available.
Bring the same evidence-first view to your own health data.
LongevityMate organises blood work, optional wearable context and goals to help you understand trends and prepare better questions. It does not diagnose, treat or replace a clinician.
See how LongevityMate worksLongevityMate Brief is educational information, not medical advice. Questions or feedback? Email hello@longevitymate.com.